R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Combined modality therapy has then emerged as the standard of care for limited-stage
Hodgkin's lymphoma and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
chemotherapy that is devoid of alkylating agents and associated with a low potential for
gonadal toxicity and leukemogenesis, is currently considered a gold standard. Nevertheless,
the disadvantage to combine radiotherapy to ABVD is represented by late cardiovascular events
(myocardial dysfunction and coronary or valvular disease), especially when the heart is
within the radiation field; bleomycin pulmonary toxicity also is increased in conjunction
with RT and secondary tumors, in particular in the RT fields. This study aims at treating
patients with limited disease with multiagent chemotherapy alone, without irradiation, and
using radiotherapy only for relapses.